New Drug Approvals

Home » Phase2 drugs » PF-04136309




Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 


Recent Posts

Blog Stats

  • 3,947,661 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,725 other followers

add to any



Image result for PF-04136309

PF 4136309

PF4136309; PF 4136309; PF-4136309; PF04136309; PF4136309; PF-04136309; INCB8761; INCB 8761; INCB-8761



N-[2-((3S)-3-[4-hydroxy-4-(4-pyrimidin-2-ylphenyl)cyclohexyl]aminopyrrolidin-1-yl)-2- oxoethyl]-3-(trifluoromethyl)benzamide

MF: C29H31F3N6O3
MW: 568.24097

CC chemokine receptor 2 (CCR2) antagonist

Image result for PFIZER

Pfizer Limited

Gary Burgess

Image result for INCYTE

PF-4136309, also known as INCB8761, is an orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist PF-04136309 specifically binds to CCR2 and prevents binding of the endothelium-derived chemokine ligand CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and signal transduction. This may inhibit inflammatory processes as well as angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays an important role in inflammation, angiogenesis, and tumor cell migration and proliferation.

  • Originator Pfizer
  • Class Analgesics
  • Mechanism of Action CCR2 receptor antagonists

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • Discontinued Hepatic fibrosis; Pain

Most Recent Events

  • 01 Apr 2016 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in USA (PO) (NCT02732938)
  • 01 Dec 2015 Phase-I clinical trials in Pancreatic cancer (In volunteers) in Belgium (PO) (NCT02598206)
  • 09 Nov 2015 Pfizer plans a phase I trial in Healthy volunteers in Belgium and USA (NCT02598206)



MS (M+H)+:569.2.

1H NMR (400 MHz, CD3OD): δ 9.57 – 9.45 (m, 1H), 8.94-8.84 (m, 2H), 8.82 –
8.72 (m, 1H), 8.27 – 8.19 (m, 1H), 8.15 (d, J = 7.8 Hz, 1H), 7.91 – 7.84 (m, 2H), 7.69
(dd, J = 7.8, 7.8 Hz, 1H), 7.46-7.39 (m, 1H), 4.29 – 4.12 (m, 2H), 3.87 (dd, J = 10.1, 6.4
Hz, 0.5H), 3.83 – 3.39 (m, 3.5H), 3.38 – 3.32 (m, 1H), 3.02 – 2.91 (m, 1H), 2.51 – 2.35
(m, 2H), 2.34 – 2.14 (m, 1H), 2.13 – 1.88 (m, 2.5H), 1.88 – 1.76 (m, 0.5H), 1.74 – 1.56
(m, 4H).

Anal. (C29H31F3N6O3): calcd C 61.24, H 5.50, N 14.79; found C 61.18, H 5.59,
N 14.87.




LC-MS (M+H)+: 316.1/314.1. 1H NMR (300 MHz,CDCl3): δ 8.60 (s, 1 H), 7.82 (d, 1 H), 7.38 (d, 1 H), 4.6 (s, 1 H), 4.0 (m, 4 H), 2.2 (m, 4
H), 1.7 (m, 4 H).



LC-MS (M+H)+: 314.2.




(M+H)+: 270.2.

tert-Butyl [(S)-1-({[3-(Trifluoromethyl)benzoyl]amino}acetyl)


MS (M-Boc+H)+: 316.


benzamide hydrochloride


(M+H)+: 316.




WO 2012114223

Example 35

Step A

Figure imgf000062_0002

8-(4-lodo-phenyl)-1 ,4-dioxa-spiro[4.5]decan-8-ol. To a solution of 1 ,4-diiodobenzene (16.5 g, 50 mmol) in THF (350 mL) at -78°C was added n-BuLi (2.5 M, 24 mL) over 1 hour. After stirred additional 30 minutes, a solution of 1 ,4-dioxa-spiro[4.5]decan-8-one (7.8 g, 50 mmol) in THF (30 mL) was added in and the resulting mixture was stirred for 3 hours. To the mixture was added TMSCI (5.4 g, 50 mmol) and the resulting mixture was allowed to warm to rt and stirred at rt for 18 hours. The reaction mixture was neutralized to pH 6.0, and extracted with ethyl acetate (3X 50 mL). The organic extracts were combined, washed with saline solution (2X 50 mL), dried over sodium sulfate, concentrated in vacuo. The residue was chromatographed on silica gel, eluting with hexane/ethyl acetate (95/5 to 100/0). The appropriate fractions were combined to give 8-(4-lodo-phenyl)-1 ,4-dioxa-spiro[4.5]decan-8-ol (12 g, 66.6%) with LCMS: 361 .2 (M+H+, 100%) and {[8-(4-iodophenyl)-1 ,4- dioxaspiro[4.5]dec-8-yl]oxy}(trimethyl)silane (6 g, 27%) with LCMS: 433.1 (M+H+, 100%). Step B

Figure imgf000063_0001

8-(4-pyrimidin-2-ylphenyl)-1 ,4-dioxaspiro[4.5]decan-8-ol. To a solution of 8-(4-iodo- phenyl)-1 ,4-dioxa-spiro[4.5]decan-8-ol (450.0 mg, 1.249 mmol) in THF (1.0 mL) at room temperature was added dropwise isopropylmagnesium chloride (2.0 M in THF, 1 .37 mL) and the reaction mixture was stirred at room temperature for 30 mins. To another flask charged with nickel acetylacetonate (20 mg, 0.06 mmol) and 1 ,3-bis(diphenylphosphino)-propane (26 mg, 0.062 mmol) suspened in THF (3 mL) under N2 was added 2-bromopyrimidine (199 mg, 1.25 mmol). The resulting mixture was stirred at room temperature until it is clear. The second mixture was transferred into the degassed Grignard solution prepared in step 1. The resulting mixture was stirred at room temperature overnight. The reaction mixture was diluted with EtOAc, quenched with water, washed with brine, dried overNa2S04, and concentrated. The residue was columned on silica gel, eluted with hexane/EtOAc (2/1 ), to gave the desired compound (270 mg, 69%) as white solid. LCMS: 313.1 , (M+H, 100%). 1H

NMR (CDCIs): δ 8.86 (d, 2H), 8.46 (dd, 2H), 7.71 (dd, 2H), 7.24 (t, 1 H), 4.05 (d, 4H), 2.30 (dt, 2H), 2.18 (dt, 2H), 1 .90 (m, 2H), 1 .78 (m, 2H).

Step C

Figure imgf000063_0002

4-Hydroxy-4-(4-pyrimidin-2-ylphenyl)cyclohexanone. The title compound was prepared by treating the ketal of step B with HCI in water following the procedure described in step B of Example 2. MS (M+H)+ 269.

Step D

Figure imgf000063_0003

N-[2-((3S)-3-[4-hydroxy-4-(4-pyrimidin-2-ylphenyl)cyclohexyl]aminopyrrolidin-1-yl)-2- oxoethyl]-3-(trifluoromethyl)benzamide bis(trifluoroacetate) (salt). To a 1-neck round-bottom flask charged with methylene chloride (1 ml.) was added 4-hydroxy-4-(4-pyrimidin-2- ylphenyl)cyclohexanone (50.0 mg, 0.186 mmol), N-2-[(3S)-3-aminopyrrolidin-1-yl]-2- oxoethyl-3-(trifluoromethyl)benzamide hydrochloride (65.5 mg, 0.186 mmol), and triethylamine (85.7 uL, 0.615 mmol). The resulting mixture was stirred at 25°C for 30 minutes, and to it was added sodium triacetoxyborohydride (62.4 mg, 0.28 mmol) in portion. The reaction mixture was stirring at rt overnight. The reaction was concentrated, and the residue was chromatographed on Si02, eluted with acetone/methanol (100% to 90%/10%) to give two fractions, which were further purified on prep-LCMS separately to afford F1 (24.2 mg ) and F2 (25.9 mg) as white powder in total 34% of the yield. LCMS: 568.2 (M+H, 100%)


Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist

Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880, United States
Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017, United States
ACS Med. Chem. Lett., 2011, 2 (12), pp 913–918
Tel: 302-498-6706. Fax: 302-425-2750. E-mail:
Abstract Image

We report the discovery of a new (S)-3-aminopyrrolidine series of CCR2 antagonists. Structure–activity relationship studies on this new series led to the identification of 17 (INCB8761/PF-4136309) that exhibited potent CCR2 antagonistic activity, high selectivity, weak hERG activity, and an excellent in vitro and in vivo ADMET profile. INCB8761/PF-4136309 has entered human clinical trials.


A precise and sensitive LC method was developed and further validated for the determination of enantiomeric purity of (S)-N-[2-(3-{trans-4-hydroxy-4-[5-(pyrimidin-2-yl)pyridin-2-yl] cyclohexylamino} pyrrolidin-1-yl)-2-oxoethyl]-3-(trifluoromethyl) benzamide (PF-04136309). Baseline separation with a resolution higher than 1.8 was accomplished within 40 min using a CHIRALPAK AD (250 × 4.6 mm; particle size 5 μm) column, with n-hexane:2-propanol (70:30v/v) as mobile phase at a flow rate of 1 mL min−1. The eluted analytes were subsequently detected with a UV detector at 260 nm. The effects of mobile phase components and temperature on enantiomeric selectivity as well as the resolution of enantiomers were thoroughly investigated. The calibration curves were plotted within a concentration range between 0.01 and 1 mg mL−1 (n = 9), and recoveries between 98.17 and 101.28 % were obtained, with relative standard deviation (RSD) lower than 1.44 %. The LOD and LOQ for PF-04136309 were 3.59 and 11.54 μg mL−1 and for its enantiomer were 3.39 and 11.28 μg mL−1, respectively. The developed method was demonstrated to be accurate, robust and sensitive for the determination of enantiomeric purity of PF-04136309, especially for the analysis of bulk samples.


1: Xue CB, Wang A, Han Q, Zhang Y, Cao G, Feng H, Huang T, Zheng C, Xia M, Zhang K, Kong L, Glenn J, Anand R, Meloni D, Robinson DJ, Shao L, Storace L, Li M, Hughes RO, Devraj R, Morton PA, Rogier DJ, Covington M, Scherle P, Diamond S, Emm T, Yeleswaram S, Contel N, Vaddi K, Newton R, Hollis G, Metcalf B. Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist. ACS Med Chem Lett. 2011 Oct 5;2(12):913-8. doi: 10.1021/ml200199c. eCollection 2011 Dec 8. PubMed PMID: 24900280; PubMed Central PMCID: PMC4018168.

//////1341224-83-6, PF 4136309, PF4136309,  PF 4136309, PF-4136309, PF04136309, PF4136309, PF-04136309, INCB8761, INCB 8761, INCB-8761, PFIZER, PHASE 2


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Follow New Drug Approvals on

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,725 other followers



DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK LIFE SCIENCES LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 PLUS year tenure till date June 2021, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 90 Lakh plus views on dozen plus blogs, 233 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 33 lakh plus views on New Drug Approvals Blog in 233 countries...... , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

View Full Profile →



Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.
%d bloggers like this: